GLP1R Polymorphisms and Response to GLP1

NCT00588380 · Completed

Last updated 2026-05-28

This clinical trial is testing how variations in the GLP1R gene may affect the body's response to GLP1 in people with diabetes.

Status Completed The study has finished.

Phase Not applicable Not a phased drug trial (e.g. a device or behavioral study).

Type Interventional (clinical trial)

Design open-label (no blinding) basic-science study

Participants 88 people

Who can join Ages 18–40 · all sexes Healthy volunteers accepted.

Timeline Started 2007-11 · est. completion 2010-09

Where 1 site · United States

What this study is testing ClinicalTrials.gov NCT00588380 ↗

Description as written by the study sponsor.

Glucagon-like Peptide-1 (GLP-1) is an important incretin hormone which acts as a powerful insulin secretagogue. Defects in GLP-1 synthesis and secretion are thought to be part of the pathogenesis of type 2 diabetes. Furthermore GLP-1 based therapy is an important part of the therapeutic armamentarium for the treatment of type 2 diabetes. The GLP-1 receptor (GLP1R) is the principal site of action of GLP-1 and GLP-1 receptor agonists like exenatide and liraglutide. The gene coding for this receptor, GLP1R, is highly polymorphic and contains numerous non-synonymous Single Nucleotide Polymorphisms (nsSNPs) which could potentially alter response to endogenous or exogenous GLP-1 or GLP-1R agonists. Indeed there is some in vitro data to support this concept. We propose to utilize a hyperglycemic clamp to test the insulin secretory response to infused GLP-1 in healthy volunteers to determine the effect of genetic variation in GLP1R on response to GLP-1.

Treatments tested

GLP-1 Drug

GLP-1 infused at 0.75 pmol/kg/min from 121-180 minutes, GLP-1 infused at 1.55 pmol/kg/min from 181-240 minutes,

Main thing measured	Insulin Secretion at 150-180 Minutes.
Sponsor	Mayo Clinic
Conditions studied	Diabetes
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT00588380 ↗